Publications by authors named "Silvia Ling"
Article Synopsis
- Among 85 patients analyzed, 35.3% received PCAB with additional agents, particularly bortezomib, but high rates of severe side effects like cytopenia and febrile neutropenia were observed.
- Some patients were able to successfully transition to CAR T-cell therapy, suggesting that PCAB may serve as a valuable bridge to newer treatments, warranting further study into its effectiveness.
Article Synopsis
- - Multiple myeloma (MM) is an incurable blood cancer traditionally monitored through invasive bone marrow biopsies, but recent advancements suggest liquid biopsies using cell-free DNA (cfDNA) could serve as a less invasive alternative for tracking the disease.
- - This pilot study focused on assessing the feasibility of detecting oncogenic mutations in key genes (NRAS, KRAS, BRAF) that are involved in the MAPK pathway using cfDNA from the blood of 13 MM patients, alongside matched bone marrow samples.
- - Preliminary findings indicate that mutations were present in both cfDNA and bone marrow DNA, suggesting that cfDNA could be a useful tool for screening mutations and predicting treatment outcomes in MM, although results are based on
Article Synopsis
- * There’s growing interest in creating frailty assessment tools specifically for MM patients, which can help both predict outcomes and tailor treatments based on each person's frailty level.
- * This paper reviews several frailty assessment methods, highlighting the International Myeloma Working Group Frailty Index as the most accepted tool, while also proposing a user-friendly simplified frailty scale and recommendations for using these tools in clinical practice to improve treatment strategies.
Article Synopsis
- Waldenström macroglobulinaemia (WM) is a slow-growing B-cell cancer characterized by high levels of IgM protein, specific bone marrow changes, and a prevalent mutation (MYD88 L265P) found in most patients.
- Traditional treatment has involved chemoimmunotherapy, but recent research highlights the effectiveness of Bruton tyrosine kinase inhibitors as a standalone treatment or alongside other drugs.
- The Medical and Scientific Advisory Group of Myeloma Australia has updated recommendations for managing WM, incorporating recent evidence and advancements in treatment options since their last report in 2017.
Multiple myeloma (MM) remains incurable despite high-dose chemotherapy, autologous stem cell transplants and novel agents. Even with the improved survival of MM patients treated with novel agents, including bortezomib (Bz), the therapeutic options in relapsed/refractory MM remain limited. The majority of MM patients eventually develop resistance to Bz, although the mechanisms of the resistance are poorly understood.
View Article and Find Full Text PDFImaging modalities for multiple myeloma (MM) have evolved to enable earlier detection of disease. Furthermore, the diagnosis of MM requiring therapy has recently changed to include disease prior to bone destruction, specifically the detection of focal bone lesions. Focal lesions are early, abnormal areas in the bone marrow, which may signal the development of subsequent lytic lesions that typically occur within the next 18-24 months.
View Article and Find Full Text PDFEndoplasmic reticulum stress in the development of multiple myeloma and drug resistance.
Clin Transl Immunology
January 2018
Multiple myeloma (MM) is a haematological malignancy of mature antibody-secreting plasma cells. Currently, MM is incurable, but advances in drug treatments have increased patient lifespan. One of the characteristics of MM is the excessive production of monoclonal immunoglobulin (also referred to as paraprotein).
View Article and Find Full Text PDFMultiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow. More than 80% of patients with MM display evidence of myeloma bone disease (MBD), characterised by the formation of osteolytic lesions throughout the axial and appendicular skeleton. MBD significantly increases the risk of skeletal-related events such as pathologic fracture, spinal cord compression and hypercalcaemia.
View Article and Find Full Text PDFMultiple myeloma (MM) is predominantly an incurable malignancy despite high-dose chemotherapy, autologous stem cell transplant and novel agents. MM is a genetically heterogeneous disease and the complexity increases as the disease progresses to a more aggressive stage. MM arises from a plasma cell, which produces and secretes non-functioning immunoglobulins.
View Article and Find Full Text PDFBackground: [(18)F]fluorodeoxyglucose positron emission tomography (PET) is a useful staging investigation for follicular lymphoma (FL). Recent studies have shown that positive post-treatment PET is also a strong predictor of inferior overall survival.
Purpose: To evaluate the predictive value of mid- and post-treatment PET in FL patients with respect to progression-free survival (PFS) and overall survival (OS).
Background: Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment. It remains unclear why myelomas are peculiarly sensitive to bortezomib, or what causes primary or acquired resistance.
View Article and Find Full Text PDFWe report two cases of Waldenström's macroglobulinemia with an unusual aggressive transformation following treatment with cladribine (2-chlorodeoxyadenosine, 2-CdA), a purine analogue. The first patient developed transformation to a diffuse large-cell non-Hodgkin lymphoma, while the second developed extensive extramedullary involvement. Both patients displayed rapid progression following transformation and were refractory to chemotherapy.
View Article and Find Full Text PDF